Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Debt Ratio (2022 - 2024)

Summit Therapeutics' Debt Ratio history spans 3 years, with the latest figure at 0.57 for Q1 2024.

  • For Q1 2024, Debt Ratio rose 44.19% year-over-year to 0.57; the TTM value through Mar 2024 reached 0.57, up 44.19%, while the annual FY2023 figure was 0.49, 33.83% down from the prior year.
  • Debt Ratio reached 0.57 in Q1 2024 per SMMT's latest filing, up from 0.49 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.74 in Q4 2022 to a low of 0.22 in Q1 2022.
  • Average Debt Ratio over 3 years is 0.44, with a median of 0.42 recorded in 2023.
  • The largest YoY upside for Debt Ratio was 82.37% in 2023 against a maximum downside of 33.83% in 2023.
  • A 3-year view of Debt Ratio shows it stood at 0.74 in 2022, then plummeted by 33.83% to 0.49 in 2023, then rose by 14.8% to 0.57 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Debt Ratio are 0.57 (Q1 2024), 0.49 (Q4 2023), and 0.42 (Q2 2023).